- Home
- HCWB vs BMRA Comparison
HCWB vs BMRA Comparison
Compare HCWB & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- BMRA
- Stock Information
- Founded
- HCWB 2018
- BMRA 1971
- Country
- HCWB United States
- BMRA United States
- Employees
- HCWB N/A
- BMRA N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HCWB Health Care
- BMRA Health Care
- Exchange
- HCWB Nasdaq
- BMRA Nasdaq
- Market Cap
- HCWB 10.8M
- BMRA 8.1M
- IPO Year
- HCWB 2021
- BMRA N/A
- Fundamental
- Price
- HCWB $4.30
- BMRA $3.52
- Analyst Decision
- HCWB Strong Buy
- BMRA
- Analyst Count
- HCWB 1
- BMRA 0
- Target Price
- HCWB $35.00
- BMRA N/A
- AVG Volume (30 Days)
- HCWB 116.1K
- BMRA 98.3K
- Earning Date
- HCWB 08-13-2025
- BMRA 08-27-2025
- Dividend Yield
- HCWB N/A
- BMRA N/A
- EPS Growth
- HCWB N/A
- BMRA N/A
- EPS
- HCWB N/A
- BMRA N/A
- Revenue
- HCWB $1,445,145.00
- BMRA $5,678,000.00
- Revenue This Year
- HCWB $178.36
- BMRA N/A
- Revenue Next Year
- HCWB N/A
- BMRA N/A
- P/E Ratio
- HCWB N/A
- BMRA N/A
- Revenue Growth
- HCWB N/A
- BMRA 5.01
- 52 Week Low
- HCWB $3.55
- BMRA $1.93
- 52 Week High
- HCWB $100.80
- BMRA $10.16
- Technical
- Relative Strength Index (RSI)
- HCWB 42.79
- BMRA 51.92
- Support Level
- HCWB $4.02
- BMRA $3.50
- Resistance Level
- HCWB $4.44
- BMRA $4.24
- Average True Range (ATR)
- HCWB 0.31
- BMRA 0.27
- MACD
- HCWB 0.08
- BMRA 0.03
- Stochastic Oscillator
- HCWB 31.85
- BMRA 44.62
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.